Epigenetic mediated functional reprogramming of immune cells leads to HBsAg seroconversion in Hepatitis B Virus Reactivation patients
J. K. Sevak, M. Islam, G. Verma, A. Saxena, P. Babu E, S. Parveen, A. Jindal, M. K. Sharma, G. Ramakrishna, S. K. Sarin, N. Trehanpati
Abstract
BackgroundHepatitis B virus (HBV) modulates epigenetic landscape by epigenetic regulators. HBsAg seroconversion is possible with immune activation, therefore we aimed to investigate epigenetic modulation in HBV reactivation (rHBV) for viral clearance and seroconversion. MethodsSixteen retrospectively collected rHBV patients [Seroconverters (SC, n=7, HBsAg loss and anti-HBs>10 IU/ml), non- seroconverters (NSC, n=9)], chronic hepatitis B treatment naive (nCHBV, n=7) patients and healthy controls (HC, n=7) were included in this study. Genome methylation, gene expression, plasma-cytokines, and immune cell profiling was analysed by Reduced Representation Bisulfite Sequencing (RRBS), QRT-PCR, multiplex-cytokine-bead array and flow-cytometry. ResultsrHBV patients having high HBV DNA and ALT showed epigenetic remodellers; KDM2B, NCOR2 and GATA6, immune and metabolic genes; TGF-{beta}, IL-6, IRF8, RPTOR, HK3 significantly (p View larger version (29K): org.highwire.dtl.DTLVardef@48e206org.highwire.dtl.DTLVardef@ef0fa7org.highwire.dtl.DTLVardef@ecb710org.highwire.dtl.DTLVardef@e6b34e_HPS_FORMAT_FIGEXP M_FIG C_FIG Lay summaryEpigenetic landscape in nCHBV depicts exhaustion and immune dysfunction. Out of many hypermethylated CpG islands of nCHBV, few become hypomethylated in rHBV and drives immune and metabolic reprogramming. This study provides insights into the cellular and molecular basis of epigenomic programs that regulate the differentiation and activation of immune cells leading to viral clearance and seroconversion. Targeting epigenetic mechanism could be promising strategy for the treatment of nCHBV and non-seroconverters.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition
Melanie Urbanek‐Quaing, Yin-Han Chou, … Markus Cornberg·HepatologyPeer-reviewed·Dec 19, 2024
- Clinical cure of chronic hepatitis B is dependent on activation and perpetuation of robust CD4+ T cell responses
Jillian M. Jespersen, Lia Avanesyan, … Jody L. Baron·bioRxiv·Sep 29, 2025
- Sustained liver HBsAg loss and clonal T and B cell expansion upon therapeutic DNA vaccination require low HBsAg levels
N. Conceicao-Neto, W. Pierson, … E. Van Gulck·bioRxiv·Sep 4, 2023
- Heterogeneous T cell responses across Hepatitis B virus clinical phases revealed by rapid whole-blood HBV T cell analysis
Nina Le Bert, Apostolos Koffas, … Patrick T.F. Kennedy·bioRxiv·Feb 11, 2025
- CD8 T cells with classical and NK-like cytotoxic gene expression programs mediate control of HBV replication and functional cure
Elias Isaac Lattouf, Martin Feuerherd, … Georg M. Lauer·bioRxiv·Jun 29, 2026
- The CCCTC-binding factor CTCF represses hepatitis B virus Enhancer I and regulates viral transcription
V. D'Arienzo, J. Ferguson, … J. L. Parish·Cellular MicrobiologyPeer-reviewed·Oct 16, 2020